Mucosal-associated invariant T-cells in pulmonary pathophysiology
Current Opinion in Pulmonary Medicine,
Год журнала:
2025,
Номер
unknown
Опубликована: Март 19, 2025
Purpose
of
review
Mucosal-associated
invariant
T-cells
(MAIT)
have
been
associated
with
lung
cancer
and
pulmonary
infections.
The
treatment
patients
or
infections
includes
host-directed
therapies
(HDTs).
MAIT
play
a
role
in
shaping
the
‘milieu
interne’
this
addresses
biology
pathophysiology.
Recent
findings
represent
an
attractive
target
for
therapy
malignancies
are
often
difficult
to
exploit
therapeutically
due
diversity
both
T-cell
receptor
(TCR)
repertoire
its
ligandome.
MAIT-cells
restricted
by
major
histocompatibility
complex
class
I-related
gene
protein
(MR1)
that
presents
nondefined
tumor-associated
targets,
bacterial
products,
vitamin
drug
derivates.
Due
their
plasticity
expression,
able
conversely
switch
from
IFN-γ
IL-17
production.
Both
cytokines
key
protective
immune
responses
malignancies.
MAIT-derived
production
interleukin
(IL)-17/TGF-β
shapes
tumor
micro-environment
(TME),
including
tissue
re-modelling
leading
fibrosis
recruitment
neutrophils.
contribute
gut-lung
axis
clinical
improved
checkpoint
inhibition
therapy.
at
crossroad
HDTs
targeting
malignant
infected
cells.
Clinical
presentations
overt
inflammation,
re-modeling
reviewed
along
balance
between
Th1,
Th2,
Th9,
Th17
immune-suppression
Summary
shape
TME
Drugs
affect
can
be
explored
achieve
results
while
curbing
tissue-damaging
responses.
Язык: Английский
The clinical landscape of CAR-engineered unconventional T cells
Trends in cancer,
Год журнала:
2025,
Номер
unknown
Опубликована: Март 1, 2025
Unconventional
T
cells,
such
as
invariant
natural
killer
(iNKT),
γδ
T,
and
mucosal-associated
(MAIT)
play
a
pivotal
role
in
bridging
innate
adaptive
immunity.
Their
capacity
for
rapid
tumor
targeting
effective
modulation
of
the
microenvironment
(TME)
makes
them
promising
candidates
cancer
immunotherapy.
Advances
chimeric
antigen
receptor
(CAR)
engineering
have
further
highlighted
their
therapeutic
potential,
particularly
treating
challenging
cancers.
Notably,
these
cells
exhibit
favorable
safety
profiles,
enhancing
viability
off-the-shelf
options.
We
provide
comprehensive
analysis
clinical
applications
CAR-engineered
unconventional
focusing
on
genetic
modifications,
manufacturing
processes,
preconditioning
regimens,
dosing
strategies.
discuss
successful
examples
from
recent
trials
explore
future
directions
utilizing
therapy
beyond.
Язык: Английский
TRAIL induces cytokine production via the NFkB2 pathway promoting neutrophil chemotaxis and neutrophil-mediated immune-suppression in triple negative breast cancer cells
Cancer Letters,
Год журнала:
2025,
Номер
unknown, С. 217692 - 217692
Опубликована: Апрель 1, 2025
Язык: Английский
The microbiota shapes the life trajectory of mucosal-associated invariant T cells
Trends in Microbiology,
Год журнала:
2025,
Номер
unknown
Опубликована: Апрель 1, 2025
Язык: Английский
CD161 + CD127 + CD8 + T cell subsets can predict the efficacy of anti-PD-1 immunotherapy in non-small cell lung cancer with diabetes mellitus
OncoImmunology,
Год журнала:
2024,
Номер
13(1)
Опубликована: Июнь 27, 2024
The
role
of
CD161+CD127+CD8+
T
cells
in
non-small
cell
lung
cancer
(NSCLC)
patients
with
diabetes
remains
unexplored.
This
study
determined
the
prevalence,
phenotype,
and
function
CD8+
subsets
NSCLC
diabetes.
We
recruited
(n
=
436)
treated
anti-PD-1
immunotherapy
as
first-line
treatment.
progression-free
survival
(PFS),
overall
(OS),
infiltration,
peripheral
blood
immunological
characteristics
were
analyzed
or
without
exhibited
shorter
PFS
OS
(p
0.0069
p
0.012,
respectively)
significantly
lower
infiltration.
Mass
cytometry
by
time-of-flight
(CyTOF)
showed
a
higher
percentage
among
CD8+T
before
treatment
0.0071)
than
that
this
trend
continued
after
0.0393).
Flow
multiple-immunofluorescence
confirmed
had
to
ratios
RNA-sequencing
analysis
revealed
immune-cytotoxic
genes
reduced
subset
compared
CD161+CD127−CD8+
more
cell-exhausted
phenotypes
≥
6.3%
worse
PFS.
These
findings
indicate
is
risk
factor
for
who
undergo
immunotherapy.CD161+CD127+CD8+
could
be
key
indicator
poor
prognosis
Our
would
help
advancing
therapy
Язык: Английский
Breaking the mold: Unconventional T cells in cancer therapy
Cancer Cell,
Год журнала:
2024,
Номер
unknown
Опубликована: Дек. 1, 2024
Язык: Английский
TRAIL-induced cytokine production via NFKB2 pathway promotes neutrophil chemotaxis and immune suppression in triple negative breast cancers
bioRxiv (Cold Spring Harbor Laboratory),
Год журнала:
2024,
Номер
unknown
Опубликована: Июль 23, 2024
Tumor
necrosis
factor-related
apoptosis-inducing
ligand
(TRAIL)
is
a
potential
cancer
therapeutic
that
induces
apoptosis
in
cells
while
sparing
the
non-malignant
preclinical
models.
However,
its
efficacy
clinical
trials
has
been
limited,
suggesting
unknown
modulatory
mechanisms
responsible
for
lack
of
TRAIL
activity
patients.
Here,
we
hypothesized
treatment
elicits
transcriptional
changes
triple
negative
breast
(TNBC)
alter
immune
milieu.
To
test
this,
performed
an
RNAseq
analysis
MDA-MB-231
treated
with
TRAIL,
followed
by
validation
additional
TNBC
cell
lines.
significantly
expression
multiple
cytokines
such
as
CXCLs
1,
2,
3,
8,11
and
IL-6,
which
are
known
to
modify
neutrophil
function.
Mechanistically,
induction
these
was
predominantly
mediated
death
receptor
5,
caspase
8
(but
not
enzymatic
activity),
non-canonical
NFKB2
pathway.
The
produced
TRAIL-treated
enhanced
chemotaxis
healthy
human
donor
isolated
neutrophils.
Язык: Английский